Z
Zura Bio Limited (ZURA)
NCM – Real Time Price. Currency in USD
4.75
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
4.75
0.00 (0.00%)
At close: May 12, 2026, 4:00 PM EDT
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
| Name | Position |
|---|---|
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development |
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, CEO & Director |
| Dr. Someit Sidhu M.D. | Co-Founder & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | zura-20260507.htm |
| 2026-04-30 | DEF 14A | tm261622-1_def14a.htm |
| 2026-04-23 | 8-K | tm2612540d1_8k.htm |
| 2026-03-19 | 8-K | tm269296d1_8k.htm |
| 2026-03-19 | 10-K | zura-20251231x10k.htm |
| 2026-03-10 | 8-K | tm268344d1_8k.htm |
| 2026-03-05 | 8-K | tm268054d1_8k.htm |
| 2026-02-26 | 8-K/A | tm267392d1_8ka.htm |
| 2026-02-26 | 8-K | tm267297d1_8k.htm |
| 2026-02-23 | 8-K | tm267035d1_8k.htm |